EPMA Journal

, Volume 9, Issue 2, pp 125–131 | Cite as

Diabetes care in figures: current pitfalls and future scenario

  • Alexandre Assuane Duarte
  • Shahriar Mohsin
  • Olga Golubnitschaja
Mini Review


Diabetes mellitus (DM) epidemic—on a global scale—is a major and snowballing threat to public health, healthcare systems and economy, due to the cascade of pathologies triggered in a long-term manner after the DM manifestation. There are remarkable differences in the geographic disease spread and acceleration of an increasing DM prevalence recorded. Specifically, the highest initial prevalence of DM was recorded in the Eastern-Mediterranean region in 1980 followed by the highest acceleration of the epidemic characterised by 0.23% of an annual increase resulted in 2.3 times higher prevalence in the year 2014. In contrast, while the European region in 1980 demonstrated the second highest prevalence, the DM epidemic developments were kept much better under control compared to all other regions in the world. Although both non-modifiable and modifiable risk factors play a role in DM predisposition, cross-sectional investigations recently conducted amongst elderly individuals demonstrate that ageing as a non-modifiable risk factor is directly linked to unhealthy lifestyle as a well-acknowledged modifiable risk factor which, in turn, may strongly promote ageing process related to DM even in young populations. Consequently, specifically modifiable risk factors should receive a particular attention in the context of currently observed DM epidemic prognosed to expand significantly over 600 million of diabetes-diseased people by the year 2045. The article analyses demographic profiles of DM patient cohorts as well as the economic component of the DM-related crisis and provides prognosis for future scenarios on a global scale. The innovative approach by predictive diagnostics, targeted prevention and treatments tailored to the person in a suboptimal health condition (before clinical onset of the disease), as the medicine of the future is the most prominent option to reverse currently persisting disastrous trends in diabetes care. The key role of biomedical sciences in the future developments of diabetes care is discussed.


Diabetes mellitus Epidemic Comorbidities Prevalence Medical care Costs Economy Health policy Adolescence Predictive preventive personalised medicine Prognose Pitfalls 



The authors thank the European Association for Predictive, Preventive and Personalised Medicine (EPMA, Brussels) for professional and financial support of the project.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Patients have not been involved in the study.

Human and animal rights

No experiments have been performed including patients and/or animals.


  1. 1.
    Golubnitschaja O. In: Mozaffari M, editor. Three levels of prediction, prevention and individualised treatment algorithms to advance diabetes care: integrative approach. pp. 11–28. In book New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM. Dordrecht: Springer; 2013.Google Scholar
  2. 2.
    World Health Organization. Global report on diabetes. 2016; ISBN 978 92 4 156525 7, viewed on February 1st 2018.
  3. 3.
    NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530.
  4. 4.
    Parkkola A, Laine AP, Karhunen M, Härkönen T, Ryhänen SJ, Ilonen J, et al. HLA and non-HLA genes and familial predisposition to autoimmune diseases in families with a child affected by type 1 diabetes. PLoS One. 2017;12(11):e0188402. Scholar
  5. 5.
    Mercader JM, Florez JC. The genetic basis of type 2 diabetes in Hispanics and Latin Americans: challenges and opportunities. Front Public Health. 2017;5:329. Scholar
  6. 6.
    Luo B, Zhang J, Hu Z, Gao F, Zhou Q, Song S, et al. Diabetes-related behaviours among elderly people with pre-diabetes in rural communities of Hunan, China: a cross-sectional study. BMJ Open. 2018;8(1):e015747. Scholar
  7. 7.
    International Diabetes Federation. IDF Diabetes Atlas, 7 th edn. Brussels, Belgium: International Diabetes Federation, 2015; viewed on February 1st 2018.
  8. 8.
    International Diabetes Federation. IDF Diabetes Atlas, 8th Edition, 2017.
  9. 9.
    Golubnitschaja O. Advanced diabetes care: three levels of prediction, prevention and personalized treatment. Curr Diabetes Rev. 2010;6:42–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Yeghiazaryan K, Cebioglu M, Golubnitschaja O. In: Mozaffari M, editor. Global figures argue in favour of preventive measures and personalised treatment to optimise inadequate diabetes care. pp. 1–13. In book New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM. Dordrecht: Springer; 2013.Google Scholar
  11. 11.
    Cebioglu M, Schild HH, Golubnitschaja O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J. 2010;1(1):130–7. Scholar
  12. 12.
    Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy: results of the Seattle Prospective Diabetic Foot Study. Diabetes Care. 1997;20(7):1162–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):1879–82. Scholar
  14. 14.
    Illigens BM, Gibbons CH. A human model of small fiber neuropathy to study wound healing. PLoS One. 2013;8(1):e54760. Scholar
  15. 15.
    Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, et al. Human skin wounds: a major and snowballing threat to public health and economy. Wound Repair Regen. 2009;17(6):763–71. Scholar
  16. 16.
    Avishai E, Yeghiazaryan K, Golubnitschaja O. Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J. 2017;8(1):23–33. Scholar
  17. 17.
    Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. PharmacoEconomics. 2015;33(8):811–31. Scholar
  18. 18.
    Institute for Alternative Futures. United States’ diabetes crisis: today and future trends. Diabetes 2025 Forecasts, 2011;
  19. 19.
    Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation—EPMA position paper 2016. EPMA J. 2016;7:23. Scholar

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2018

Authors and Affiliations

  • Alexandre Assuane Duarte
    • 1
  • Shahriar Mohsin
    • 2
  • Olga Golubnitschaja
    • 3
    • 4
    • 5
  1. 1.Instituto Master de Ensino Presidente Antonio Carlos (IMEPAC)AraguariBrazil
  2. 2.CEMBIORhinische Friedrich-Wilhelms-University of BonnBonnGermany
  3. 3.Radiological ClinicRheinische Friedrich-Wilhelms-Universität BonnBonnGermany
  4. 4.Breast Cancer Research CentreRheinische Friedrich-Wilhelms-Universität BonnBonnGermany
  5. 5.Centre for Integrated Oncology, Cologne-BonnRheinische Friedrich-Wilhelms-Universität BonnBonnGermany

Personalised recommendations